What is Innerwell?
Innerwell offers a comprehensive approach to mental health, combining at-home psychedelic therapy with the support of licensed therapists. Their services span traditional psychiatry, therapy, and advanced treatments like ketamine and EMDR, targeting conditions such as depression, anxiety, and PTSD. The company's core mission is to enhance mental health outcomes through personalized, evidence-based care.
How much funding has Innerwell raised?
Innerwell has raised a total of $3M across 1 funding round:
Other Financing Round
$3M
Other Financing Round (2022): $3M with participation from Greycroft Partners, Looking Glass, and Max-Ventures
Key Investors in Innerwell
Greycroft Partners
Greycroft is a venture capital firm specializing in internet and mobile markets, known for leveraging its extensive network to support entrepreneurs in building successful businesses.
Looking Glass
Looking Glass is an investor participating in Innerwell's funding round, contributing to the company's growth in the mental health sector.
Max-Ventures
Max-Ventures is a venture capital firm based in Cleveland, Ohio, focused on investments within the Venture Capital & Private Equity industry.
What's next for Innerwell?
The substantial enterprise-level funding indicates Innerwell is poised for significant scaling and expansion. This capital injection will likely fuel further development of their therapeutic platforms, broader geographic reach across the U.S., and enhanced integration of their innovative treatment modalities. The strategic nature of the recent investment suggests a focus on solidifying market position and potentially forging key partnerships within the healthcare ecosystem.
See full Innerwell company page
